Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To determine if specific biomarkers (troponin I and B-type natriuretic peptide \[BNP\]) detect cardiotoxicity earlier than standard clinical means in patients receiving sunitinib malate (SU11248) or sorafenib chemotherapy.
SECONDARY OBJECTIVES:
I. To prospectively evaluate the incidence and severity of cardiac toxicity related to sunitinib or sorafenib during chemotherapy.
OUTLINE:
Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient age 18-85 years
Starting a new course of chemotherapy at MD Anderson Cancer Center that includes sunitinib or sorafenib
Has a life expectancy of greater than 6 months
You may not be if
Unstable angina within the last 3 months
Myocardial infarction within the last 3 months
Left ventricular ejection fraction (LVEF) less than 40%
Decompensated heart failure (HF) in the last 3 months
